{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T21:27:25Z","timestamp":1772659645591,"version":"3.50.1"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.blre.2022.100949","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T20:54:54Z","timestamp":1648241694000},"page":"100949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A review of pathobiology and therapies for classic Hodgkin lymphoma"],"prefix":"10.1016","volume":"55","author":[{"given":"Maliha","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0005","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2022.100949_bb0010","author":"Surveillance, Epidemiology, and End Results Program"},{"key":"10.1016\/j.blre.2022.100949_bb0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100949_bb0020","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.100949_bb0025","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin\u2019s disease in relapse or failure after initial chemotherapy: results of the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte H89 Trial","volume":"20","author":"Ferme","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100949_bb0030","first-page":"CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2022.100949_bb0045","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100949_bb0050","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2022.100949_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2022.100949_bb0060","doi-asserted-by":"crossref","first-page":"e28602","DOI":"10.4161\/cib.28602","article-title":"On the origin of giant cells in Hodgkin lymphoma","volume":"7","author":"Rengstl","year":"2014","journal-title":"Commun Integr Biol"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.blre.2022.100949_bb0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.hoc.2007.06.016","article-title":"The pathogenesis of classical Hodgkin\u2019s lymphoma: a model for B-cell plasticity","volume":"21","author":"Mathas","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"10.1016\/j.blre.2022.100949_bb0085","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma","volume":"23","author":"Re","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100949_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"10.1016\/j.blre.2022.100949_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.185","article-title":"Reed-Sternberg cells in Hodgkin\u2019s lymphoma present features of cellular senescence","volume":"7","author":"Gopas","year":"2016","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0100","first-page":"116","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0105","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2022.100949_bb0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol"},{"issue":"57","key":"10.1016\/j.blre.2022.100949_bb0125","article-title":"Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma","volume":"11","author":"Wang","year":"2018","journal-title":"J HematolOncol"},{"issue":"8803","key":"10.1016\/j.blre.2022.100949_bb0130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0140-6736(92)91135-U","article-title":"Response of refractory Hodgkin\u2019s disease to monoclonal anti-CD30 immunotoxin","volume":"339","author":"Falini","year":"1992","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0135","first-page":"1779","article-title":"A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma","volume":"8","author":"Schnell","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.blre.2022.100949_bb0140","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2005.09.098","article-title":"Treatment of refractory Hodgkin\u2019s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody","volume":"23","author":"Schnell","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100949_bb0150","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9980","key":"10.1016\/j.blre.2022.100949_bb0155","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"issue":"18","key":"10.1016\/j.blre.2022.100949_bb0160","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100949_bb0165","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","article-title":"Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.blre.2022.100949_bb0175","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0180","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0185","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100949_bb0190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0195","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-77-6-861","article-title":"Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients","volume":"77","author":"Yagoda","year":"1972","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0200","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.blre.2022.100949_bb0205","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin\u2019s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2022.100949_bb0210","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.blre.2022.100949_bb0215","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100949_bb0225","series-title":"Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III\/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. In62nd American Society of Hematology Annual Meeting and Exposition","author":"Straus","year":"2020"},{"issue":"26","key":"10.1016\/j.blre.2022.100949_bb0230","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2022.100949_bb0235","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood."},{"issue":"30","key":"10.1016\/j.blre.2022.100949_bb0240","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0245","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100949_bb0250","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"105","author":"Kersten","year":"2020","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.100949_bb0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100949_bb0260","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0270","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100949_bb0275","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","article-title":"Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma","volume":"3","author":"Picardi","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2022.100949_bb0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2022.100949_bb0285","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100949_bb0290","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0295","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100949_bb0300","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0305","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2022.100949_bb0310","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0315","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0320","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2022.100949_bb0325","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 rtial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2022.100949_bb0330","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100949_bb0335","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0340","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist."},{"issue":"11","key":"10.1016\/j.blre.2022.100949_bb0350","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100949_bb0355","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"31","key":"10.1016\/j.blre.2022.100949_bb0360","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2022.100949_bb0365","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2022.100949_bb0370","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"Supplement1","key":"10.1016\/j.blre.2022.100949_bb0375","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2019-127280","article-title":"Three-year follow-up of Keynote-087: pembrolizumab monotherapy in relapsed\/refractory classic Hodgkin lymphoma","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood."},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100949_bb0380","article-title":"Pembrolizumab Improves Progression-Free Survival in Relapsed\/Refractory Hodgkin Lymphoma","volume":"25 Suppl 1","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0385","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2022.100949_bb0390","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0395","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2022.100949_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0405","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0410","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0415","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0420","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0425","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.blre.2022.100949_bb0430","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.blre.2022.100949_bb0435","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0440","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0445","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-11-4513","article-title":"A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas","volume":"106","author":"Jundt","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100949_bb0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"136","key":"10.1016\/j.blre.2022.100949_bb0455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140507","article-title":"Everolimus Plus Itacitinib in Relapsed\/Refractory Classical Hodgkin Lymphoma: Results of a Phase I\/II Investigator Initiated Trial (EVITA Study)","author":"Svoboda","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100949_bb0460","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0465","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0470","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14712598.1.4.675","article-title":"Immunotherapeutic and antitumour potential of thalidomide analogues","volume":"1","author":"Marriott","year":"2001","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"10.1016\/j.blre.2022.100949_bb0475","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0480","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjh.15741","article-title":"Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial","volume":"185","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0485","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J Cell Biochem"},{"issue":"32","key":"10.1016\/j.blre.2022.100949_bb0490","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2022.100949_bb0495","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.blre.2022.100949_bb0500","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0505","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group study S0517","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2022.100949_bb0510","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2019-123163","article-title":"Preliminary results from a phase I Trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0515","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2010.08342.x","article-title":"The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism","volume":"151","author":"Buglio","year":"2010","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.blre.2022.100949_bb0520","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2011-01-331421","article-title":"The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines","volume":"119","author":"Lemoine","year":"2012","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2022.100949_bb0525","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V108.11.2260.2260","article-title":"The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib","volume":"108","author":"Georgakis","year":"2006","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0530","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","article-title":"Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Hu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2022.100949_bb0535","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clml.2017.05.008","article-title":"A phase I\/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma","volume":"17","author":"Maly","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100949_bb0540","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100949_bb0545","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137451","article-title":"Preliminary results of a phase 2 study of camidanlumab tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2022.100949_bb0550","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100949_bb0555","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2018-99-118506","article-title":"A phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed\/refractory hodgkin lymphoma after brentuximab vedotin failure: updated safety and efficacy data","volume":"132","author":"Bartlett","year":"2018","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0565","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100949_bb0570","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0575","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100949_bb0580","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.blre.2022.100949_bb0585","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.blre.2022.100949_bb0590","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100949_bb0595","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30(+) lymphoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2022.100949_bb0600","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2022.100949_bb0605","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR-Tcell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:05Z","timestamp":1759436825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":119,"alternative-id":["S0268960X22000236"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100949","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of pathobiology and therapies for classic Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100949"}}